Buch, Englisch, 406 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 630 g
Volume 3: Druggable Targets and In Silico Update
Buch, Englisch, 406 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 630 g
ISBN: 978-0-323-95578-2
Verlag: William Andrew Publishing
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
Autoren/Hrsg.
Weitere Infos & Material
PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 1. SARS-CoV-2 genome sequencing and promising druggable targets 2. Signaling pathways implicated in SARS-CoV2 infection 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease 4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions
PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry